New Development of CAR T-Cell Product Therapies
A recent partnership between Blubird Bio and TC BioPharm has been formed with the intent of developing Gamma Delta CAR T-Cell product therapies for cancer treatment. The agreement was put into place to expand TC BioPharm’s existing Gamma Delta CAR T-Cell program through clinical trials.
“Emerging research suggests that gamma delta T cells may constitute a powerful platform for CAR T cell therapies,” Philip Gregory, PhD, chief scientific officer at bluebird, said in a press release. “TCB is a leader in the gamma delta T cell field, with extensive capabilities spanning early research, clinical development and manufacturing. The combination with our deep expertise in CAR T cell biology, translational and clinical experience with leading CAR T cell drug products, and powerful gene therapy toolbox, offers a high degree of synergy.”
TC BioPharm’s current gamma delta T-Cell program is a platform called ImmuniCar, which works by genetically modifying a patient’s gamma delta T-cells in order to help doctors distinguish between healthy and diseased cells. This is very beneficial because it offers a safer approach than the current procedures that night damage healthy tissue. The two companies will work together to create products that can help target both solid and liquid tumors, like ones found in blood cancer.
“We are delighted to be working alongside bluebird bio to discover and develop next-generation CAR T cell therapies based on our innovative ImmuniCAR platform,” said Michael Leek, PhD, chief executive and founder of TC BioPharm. “The collaboration with bluebird bio, a leader in cell and gene therapy, recognizes the enormous potential of ImmuniCAR to deliver life-changing medicines,” added Artin Moussavi, PhD, chief business officer at TC BioPharm.
The partnership will utilize the benefits from TC BioPharm’s program ImmuniCAR and Blue Bird’s knowledge and experience in CAR T-Cell research and product development to create proprietary and revolutionary tumor therapy products.
As stated in the agreement, TC BioPharm will manage the first phase of the project, which includes clinical research and development. After the first phase, Blue Bird will take over to do their own clinical trials and begin product development and commercialization.